Topical glaucoma medications: Clinical implications for the ocular surface

Research output: Contribution to journalReviewResearchpeer-review

Documents

  • Fulltext

    Final published version, 1.56 MB, PDF document

  • Fredrik Fineide
  • Neil Lagali
  • Muhammed Yasin Adil
  • Reiko Arita
  • Kolko, Miriam
  • Jelle Vehof
  • Tor P. Utheim

Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.

Original languageEnglish
JournalOcular Surface
Volume26
Pages (from-to)19-49
ISSN1542-0124
DOIs
Publication statusPublished - 2022

Bibliographical note

Funding Information:
Tor Paaske Utheim is co-founder and co-owner of The Norwegian dry eye clinic and the Clinic of eye health, Oslo, Norway, which delivers talks for and/or receives financial support from the following: ABIGO, Alcon, Allergan, AMWO, Bausc'h&Lomb, Bayer, European school for advanced studies in ophthalmology, InnZ Medical, Medilens Nordic, Medistim, Novartis, Santen, Specsavers, Shire Pharmaceuticals and Thea Laboratories. He has served on the global scientific advisory board for Novartis and Alcon as well as the European advisory board for Shire Pharmaceuticals. Utheim is the Norwegian Global Ambassador for Tear Film and Ocular Surface Society (TFOS), a Board Member of the International Ocular Surface Society, an International Member of the Japanese Lid and Meibomian gland working group (LIME), a Consultant at the Norwegian Association for the Blind and Partially Sighted, the President of the Oslo Society of ophthalmology, and the Editor-in-Chief of Oftalmolog, an eye journal distributed to all eye doctors in the Nordic region since 1980. Besides publishing articles of presumed interest to our readers, Oftalmolog publishes advertisements from pharmaceutical companies, companies selling ophthalmological equipment, and associations organizing conferences and events in ophthalmology. For more information, visit: oftalmolog.com .

    Research areas

  • Dry eye disease, Eyedrops, Glaucoma, Meibomian gland dysfunction, Topical medications

Number of downloads are based on statistics from Google Scholar and www.ku.dk


No data available

ID: 318205833